Kalehua Capital Management LLC Invests $4.76 Million in uniQure N.V. $QURE

Kalehua Capital Management LLC purchased a new stake in uniQure N.V. (NASDAQ:QURE) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 291,109 shares of the biotechnology company’s stock, valued at approximately $4,760,000. uniQure accounts for about 3.4% of Kalehua Capital Management LLC’s holdings, making the stock its 11th biggest holding.

A number of other institutional investors have also recently modified their holdings of QURE. China Universal Asset Management Co. Ltd. grew its holdings in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares during the period. Arizona State Retirement System lifted its holdings in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 627 shares during the period. Ensign Peak Advisors Inc boosted its position in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 650 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of uniQure by 42.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Price Performance

Shares of NASDAQ QURE opened at $38.97 on Monday. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a market capitalization of $2.46 billion, a PE ratio of -11.20 and a beta of 0.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm’s 50-day moving average is $35.94 and its two-hundred day moving average is $25.68.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. Equities analysts anticipate that uniQure N.V. will post -3.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on QURE. The Goldman Sachs Group raised their price objective on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Leerink Partners increased their target price on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Finally, Mizuho lifted their price objective on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and an average target price of $64.17.

Insider Buying and Selling

In other uniQure news, Director Jack Kaye sold 21,167 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the transaction, the director owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. This trade represents a 44.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the transaction, the director directly owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 433,229 shares of company stock worth $17,944,799 in the last 90 days. Corporate insiders own 4.65% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.